ÂÜÀòÂÒÂ×

David Hewitt has served as a chief medical officer at Allay Therapeutics since July 2021. He is a neurologist with a successful career in pharmaceutical clinical development spanning two decades.

Prior to Allay, David was senior vice president, clinical development at Nura Bio. David joined Nura Bio from Karuna Therapeutics, where he served as senior vice president of clinical development. Previously, he was vice president of neuroscience and pain at Syneos Health. He also served in the neurology group at Merck, where he led the pediatric program for the treatment of migraines and the successful pediatric filing for Maxalt and worked on the BACE program for the treatment of prodromal Alzheimer’s disease. David began his career in biopharma at the Ortho-McNeil division of Johnson & Johnson, where he designed and conducted clinical trials in acute and chronic pain and migraine. He also worked on a large postoperative pain program that led to the approval of the drug-device system Ionsys.

David earned his MD at the University of Rochester School of Medicine, served a residency at New York Hospital Cornell Medical Center, and then a fellowship in pain, palliative care and analgesic research at Memorial Sloan-Kettering Cancer Center. He then spent six years at Emory University leading its pain and headache clinic and conducting industry-based clinical trials.